<DOC>
	<DOCNO>NCT01055847</DOCNO>
	<brief_summary>This multicenter placebo-controlled study evaluate safety efficacy AI two dosage level compare placebo CF patient P. aeruginosa lung infection .</brief_summary>
	<brief_title>Aztreonam Inhalation ( AI ) Patients With Cystic Fibrosis &amp; P. Aeruginosa Infection</brief_title>
	<detailed_description>This multicenter placebo-controlled study evaluate safety efficacy 14-day treatment AI two dosage level compare placebo , give twice daily , CF patient P. aeruginosa lung infection , deliver eFlow investigational nebulizer .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Pseudomonas Infections</mesh_term>
	<mesh_term>Aztreonam</mesh_term>
	<criteria>Written inform consent prior performance study related procedure . 13 year age . Documented sweat chloride ≥ 60 mEq/L quantitative pilocarpine iontophoresis test ( QPIT ) homozygosity ΔF508 genetic mutation heterozygosity two well characterized mutation . Ability perform pulmonary function test . FEV1 ≥ 40 % predict Visit 1 ( Screening ) . SaO2 ≥ 90 % Visit 1 ( Screening ) . P. aeruginosa present sputum Visit 1 ( Screening ) . Ability expectorate sputum daily basis . Administration antibiotic antipseudomonal activity route within 56 day prior Visit 1 ( Screening ) . Administration investigational drug device within 28 day Visit 1 ( Screening ) within 6 halflives investigational drug . Oral corticosteroid dose exceed 10 mg per day 20 mg every day . History sputum culture throat swab culture yield B. cepacia previous two year . Current daily continuous oxygen supplementation requirement 2 L/min night . Known local systemic hypersensitivity monobactam antibiotic . Changes antimicrobial , bronchodilator , antiinflammatory corticosteroid medication within 7 day prior Visit 1 ( Screening ) . Changes physiotherapy technique schedule within 7 day prior Visit 1 ( Screening ) . History lung transplantation . A chest radiograph Visit 1 ( Screening ) within previous 90 day Screening , abnormalities indicate significant acute finding ( eg , lobar infiltrate atelectasis , pneumothorax , pleural effusion ) . Abnormal renal hepatic function serum chemistry Visit 1 ( Screening ) : AST , ALT &gt; 2.5 time upper limit normal range . Creatinine &gt; 1.5 time upper limit normal range . Positive pregnancy test . All woman childbearing potential test . Female childbearing potential lactating practice acceptable method birth control ( eg , hormonal barrier method , IUD ) . Findings Visit 1 ( Screening ) , investigator 's opinion , would compromise safety patient quality study data .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>cystic fibrosis</keyword>
	<keyword>CF</keyword>
	<keyword>aztreonam</keyword>
	<keyword>lung infection</keyword>
	<keyword>Pseudomonas aeruginosa</keyword>
</DOC>